Navigation Links
'Clinical and Economical Considerations For IV Push Drug Delivery' by Industry Expert Richard Rosenfeld Is Now Accessible on Expert411.com for Media and Professional Use
Date:12/27/2007

ENGLEWOOD, Colo., Dec. 27 /PRNewswire/ -- The "Clinical and Economical Considerations For IV Push Drug Delivery" technical paper -- authored by Industry Expert Richard Rosenfeld, RPh, MBA, for Baxa Corporation -- is now accessible at http://expert411.com/_wsn/page16.html for media and professional reference. The paper is an overview of the historical background for IV push and a model for implementation of a successful program.

IV push of cephalosporin antibiotics and other drugs is an alternative method of administration that can be safe, efficacious and cost effective. This paper concentrates on IV push of cefazolin as a case study, since it is a high-use cephalosporin with physical and chemical properties similar to other drugs that can be administered by the IV push method.

Rosenfeld has personally implemented the use of IV push antibiotics within two hospital systems. During the first year that this IV push program was in place, more than 50,000 doses of cefazolin were administered by the IV push method with no occurrences of phlebitis or adverse drug events directly associated with the change in the administration method of this drug. The paper discusses the economical advantages of moving to IV push, as well as the resulting nurse satisfaction and patient benefits seen through the resulting research followup.

Executive Director of Pharmacy Management for the Scripps Health Hospital System in San Diego, CA, Rosenfeld has responsibility for all system pharmacy services through his position with Cardinal Technology and Services. Prior to joining the Scripps Health team, he served as a consultant at Sharp Healthcare, a five-hospital IDN in San Diego, California, where the IV push method of administration for cephalosporins was implemented.

Rosenfeld earned a BS in Pharmacy from Ferris State University and a BA in Chemistry from San Diego State University. He holds
'/>"/>

SOURCE Baxa Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014 Shimadzu Scientific ... amino acid analysis system developed jointly with Ajinomoto ... Station can analyze 38 amino acids in nine ... Station achieves high-speed analysis utilizing a fast application-specific ... provides accurate analytical results even under conditions with ...
(Date:7/23/2014)... StemGenex® , the leading resource ... aimed at improving the lives of patients dealing with ... Parkinson’s disease. StemGenex believes that a commitment to ... paramount when providing care to patients with degenerative diseases. ... therapy accessible to the millions of individuals currently living ...
(Date:7/23/2014)... BRUSSELS , July 23, 2014 regulated ... its research and development pipeline with positive topline ... brivaracetam . This study was designed to evaluate ... (100 and 200 mg/day, without titration) compared to ... patients with partial-onset seizures, not fully controlled despite ...
(Date:7/23/2014)... 23, 2014 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic stem cell ... a multi-product healthcare company catering to the mother and child segment, ... patients across the PRC, Singapore , ... India , the Philippines and ...
Breaking Biology Technology:Shimadzu's New UF-Amino Station Provides High-Speed, Multi-Component Analysis of Amino Acids in Food & Beverage and Pharmaceutical Testing 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 4
... Technology Council has published the first-ever magazine about ... the states research base, technology-transfer process, company creation, ... Corridor that joins Chicago, Wisconsin and Minneapolis-St. Paul. ... to post excerpts from Life Sciences: Wisconsin ...
... MADISON - While the memory inside electronic devices may often ... worsen over time. , ,Now a team of scientists ... understand why. The results are published in the early online ... ,Smart cards, buzzers inside watches and even ultrasound machines all ...
... annual Wisconsin Entrepreneurs Conference got off to a dynamic start ... least a hundred entrepreneurs and industry representatives to a crash ... entrepreneurial boot camp was designed serve both veteran and novice ... a panel of seasoned industrialists. , ,Our purpose is to ...
Cached Biology Technology:Life Sciences: Wisconsin - The Smart Choice Part Two 2Life Sciences: Wisconsin - The Smart Choice Part Two 3Life Sciences: Wisconsin - The Smart Choice Part Two 4Life Sciences: Wisconsin - The Smart Choice Part Two 5Life Sciences: Wisconsin - The Smart Choice Part Two 6Life Sciences: Wisconsin - The Smart Choice Part Two 7Engineers visualize electric memory as it fades 2Engineers visualize electric memory as it fades 3Entrepreneurs get crash course for building a successful company 2Entrepreneurs get crash course for building a successful company 3
(Date:7/23/2014)... (PHILADELPHIA) The Worldwide Innovative Networking in personalized cancer ... Kimmel Cancer Center at Thomas Jefferson University ... the only member of this prestigious group in the ... the delivery of innovative personalized medicine to the patient ... patient advocacy. , "Our participation in the WIN consortium ...
(Date:7/23/2014)... by 2050, according to one of the scenarios predicted ... be advantageous to the physiology and the biochemical and ... such as Stylosanthes capitata Vogel , a legume ... Brazil., The conclusion is from a study carried out ... Ribeiro Preto Faculty of Philosophy, Sciences and Languages and ...
(Date:7/23/2014)... starfish, and corals have in common? Aside from ... that use calcium from their environment to create ... protection. , The July issue of The ... Laboratory, addresses the challenges faced by these species ... carbon dioxide rises, the world,s oceans are becoming ...
Breaking Biology News(10 mins):New partnership brings more personalized cancer treatment to Philadelphia 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 4Calcification in changing oceans explored in special issue of The Biological Bulletin 2
... air pollutant that harms humans and plants. Both climate and ... Researchers at the University of Gothenburg, Sweden, have now shown ... risk of ozone damage to plants in northern and central ... risk of ozone damage to vegetation is mainly due to ...
... German . When a cell divides, the ... to the daughter cells. Researchers at the Friedrich Miescher Laboratory ... a model organism. In cooperation with researchers at the University ... Aurora enzymes, which were already recognized as important cellular tools ...
... of engineers and scientists at the University of British Columbia ... eye for controlled and on-demand release of drugs to treat ... leading cause of vision loss among patients with diabetes. The ... in the retina, which in its advanced stages can result ...
Cached Biology News:Climate change increases the risk of ozone damage to plants 2New tasks attributed to Aurora proteins in cell division 2New tasks attributed to Aurora proteins in cell division 3UBC researchers invent new drug delivery device to treat diabetes-related vision loss 2
Polyclonal Antibody to Coronin / CORO1C This antibody was developed against synthetic peptides corresponding to amino acids 407-420 of human CORO1C....
Peptide-affinity Purified Polyclonal Antibody to Retinoic Acid-Induced 3 (RAI3/RAIG1)...
...
Co-precipitant is free of background polynucleotides,Dnases,Rnases, proteases. 20mg/ml...
Biology Products: